Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development.

投资支持Remedium的长效蛋白治疗平台推进至首次人体临床试验阶段。

NORWALK, Conn.

康涅狄格州诺沃克

,

，

Aug. 10, 2026

2026年8月10日

/PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ('Remedium') $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company ('Lilly') and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors..

/美通社/ -- Lifespan Vision Ventures 今日宣布，其领投了 Remedium Bio, Inc.（“Remedium”）的1000万美元A轮融资，并已完成本轮融资的首次交割，礼来公司（“Lilly”）和HKX Capital参与了投资。作为此次融资的一部分，Lifespan Vision Ventures 的 Harry Robb 已加入 Remedium 董事会。

Remedium is developing durable protein therapeutics designed to enable controlled, long-lasting expression of therapeutic proteins following minimally invasive subcutaneous administration. The company's approach harnesses adipocytes as a durable site for therapeutic protein production, with the potential to provide multi-year benefit and adjustable dosing for patients with chronic diseases..

Remedium 正在开发耐用的蛋白质疗法，旨在通过微创皮下给药实现治疗性蛋白质的可控、长效表达。该公司的方法利用脂肪细胞作为治疗性蛋白质生产的持久场所，有望为慢性病患者提供长达数年的疗效和可调节的剂量。

The financing will support advancement of Remedium's lead programs, continued platform expansion, and preparation for first-in-human clinical studies.

此次融资将支持Remedium推进其核心项目、持续扩展平台，并为首次人体临床试验做好准备。

'Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy,' said Andrew Worden, Founding Partner of Lifespan Vision Ventures. 'We are proud to lead the Series A financing and support the company as it advances its pipeline toward clinical development and expands the potential of its platform.'.

“Remedium 打造了一个差异化的平台，有望解决慢性生物疗法的重要局限性，”Lifespan Vision Ventures 的创始合伙人安德鲁·沃登表示。“我们很荣幸能领投本轮 A 轮融资，并支持该公司推进其产品管线进入临床开发阶段，同时拓展其平台的潜力。”

'Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease,' said Frank Luppino, Chief Executive Officer of Remedium Bio. 'We are excited to have them lead our Series A and to welcome Harry Robb to our Board as we advance our platform, expand our pipeline, and prepare for first-in-human clinical development.'.

“Lifespan Vision Ventures 与我们一样坚信，持久疗法具有从根本上改善慢性疾病治疗的潜力。”Remedium Bio 首席执行官 Frank Luppino 表示。“我们很高兴由他们领投我们的 A 轮融资，并欢迎 Harry Robb 加入我们的董事会，与此同时，我们将推进我们的技术平台，拓展产品管线，并为首次人体临床试验做好准备。”

The financing follows recent progress across Remedium's pipeline, strategic collaborations, and preclinical programs, and is expected to support key milestones demonstrating the breadth of its platform across cardiometabolic and other chronic diseases.

此次融资紧随 Remedium 在研发管线、战略合作及临床前项目方面近期取得的进展，预计将用于支持关键里程碑的实现，以展示其平台在心脏代谢疾病及其他慢性疾病领域的广泛适用性。

About Lifespan Vision Ventures

关于 Lifespan Vision Ventures

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan..

Lifespan Vision Ventures 是一家全球性风险投资公司，专注于投资早期生物技术企业，这些企业致力于开发突破性的技术，以预防和治疗与年龄相关的疾病。该公司与富有远见的创始人合作，推动以科学为驱动的解决方案，促进健康老龄化并延长人类的健康寿命。

Contact:

联系方式：

[email protected]

[email protected]

About Remedium Bio, Inc.

关于Remedium Bio, Inc.

Remedium Bio is a biotechnology company driven by the belief that any disease can be cured. The company develops life-changing therapeutics for large unmet medical needs by advancing a revolutionary gene therapy platform that enables safe, effective, and durable delivery of therapeutic genes with simple post-treatment dose adjustment.

Remedium Bio 是一家生物技术公司，秉持着任何疾病皆可治愈的信念。公司通过推进一个革命性的基因治疗平台，开发针对重大未满足医疗需求的变革性疗法，该平台能够实现治疗基因的安全、有效和持久递送，并支持在治疗后进行简便的剂量调整。

Remedium's proprietary Prometheus™ platform aims to replace many subcutaneously administered protein therapies with single-injection, adjustable gene therapies that offer long-lasting efficacy at a fraction of the cost. The company's pipeline includes programs targeting endocrinology, immunology, neurology, and musculoskeletal diseases..

Remedium 公司专有的 Prometheus™ 平台旨在以单次注射、可调控的基因疗法取代许多皮下给药的蛋白质疗法，在以极低成本提供持久疗效的同时实现治疗方式的革新。该公司的产品管线涵盖针对内分泌学、免疫学、神经学以及肌肉骨骼疾病的治疗项目。

For more information, please visit

更多信息，请访问

www.remedium-bio.com

www.remedium-bio.com

or contact

或联系

[email protected]

[email protected]

SOURCE LifeSpan Vision Ventures

来源：LifeSpan Vision Ventures

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示